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Abstract
Background: Angiotensin-converting enzyme (ACE; Kininase II; CD143) hydrolyzes small peptides such as angiotensin I,
bradykinin, substance P, LH-RH and several others and thus plays a key role in blood pressure regulation and vascular
remodeling. Complete absence of ACE in humans leads to renal tubular dysgenesis (RTD), a severe disorder of renal tubule
development characterized by persistent fetal anuria and perinatal death.
Methodology/Principal Findings: Patient with RTD in Lisbon, Portugal, maintained by peritoneal dialysis since birth, was
found to have a homozygous substitution of Arg for Glu at position 1069 in the C-terminal domain of ACE (Q1069R)
resulting in absence of plasma ACE activity; both parents and a brother who are heterozygous carriers of this mutation had
exactly half-normal plasma ACE activity compared to healthy individuals. We hypothesized that the Q1069R substitution
impaired ACE trafficking to the cell surface and led to accumulation of catalytically inactive ACE in the cell cytoplasm. CHO
cells expressing wild-type (WT) vs. Q1069R-ACE demonstrated the mutant accumulates intracellularly and also that it is
significantly degraded by intracellular proteases. Q1069R-ACE retained catalytic and immunological characteristics of WT-
ACE N domain whereas it had 10–20% of the nativity of the WT-ACE C domain. A combination of chemical (sodium
butyrate) or pharmacological (ACE inhibitor) chaperones with proteasome inhibitors (MG 132 or bortezomib) significantly
restored trafficking of Q1069R-ACE to the cell surface and increased ACE activity in the cell culture media 4-fold.
Conclusions/Significance: Homozygous Q1069R substitution results in an ACE trafficking and processing defect which can
be rescued, at least in cell culture, by a combination of chaperones and proteasome inhibitors. Further studies are required
to determine whether similar treatment of individuals with this ACE mutation would provide therapeutic benefits such as
concentration of primary urine.
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Introduction
Angiotensin I-converting enzyme (ACE, CD143) is a Zn
2+
carboxydipeptidase which plays a key role in the regulation of blood
pressure and also in the development of vascular pathologies and
tissue remodeling [1–4]. ACE is expressed as two isoforms: somatic
ACE (sACE), which is responsible for its hypertensive properties,
and a smaller isoform (testicular ACE), which is expressed solely in
germinal cells. sACE is highly expressed in endothelial [5–6],
epithelial, neuroepithelial [7–8], and immune cells (macrophages
and dendritic cells) [9–10] as a membrane-bound protein and has
recently been designated as CD143 [11–12]. Two homologous
domains (N and C domains) comprise the majority of the structure
of sACE, each containinga functional active center [13]. The three-
dimensional structure of sACE is currently unknown, but some
indication of the interaction of the two domains has been inferred
from in silico analysis [14–16] of the recently solved crystal structures
of the N and C domains [14,17].
Numerous data convincingly indicate that elevated ACE
expression is a risk factor associated with several cardiovascular
and renal diseases such as hypertension, cardiac hypertrophy,
diabetic nephropathy, and others [18–19]. Deficiency in ACE due
to ACE inhibition or complete absence of ACE due to genetic
manipulation or mutations also leads to severe disease phenotypes
including defects in fetal development, hypotension, inability to
concentrate urine, structural renal defects, anemia, and reduced
male fertility [4,20]. In large mammals (rabbit, sheep, baboon),
ACE deficiency results in low birth weight, preterm delivery, and
fetal death [21]. In the same manner, human fetuses exposed to
ACE inhibitors during the second and third trimesters of gestation
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oligohydramnios, hypotension, growth restriction, renal tubular
dysgenesis and hypocalvaria [22]. More recently, increase risk for
congenital malformations of the cardiovascular and the central
nervous systems has been reported in infants with first trimester
exposure to the drug [21,23]. Therefore, up-regulation of ACE
expression may be an important therapeutic strategy for patients
with low ACE levels.
Two mutations in ACE have been described which were linked
to premature fetal death due to autosomal recessive renal tubular
dysgenesis -RTD [24–25], a severe disorder of renal tubular
development characterized by persistent fetal anuria and perinatal
death, probably due to pulmonary hypoplasia from early-onset
oligohydramnios (Potter phenotype). Affected individuals die in
utero or within 24 hr of birth. RTD is genetically heterogeneous
and linked to mutations in genes that encode components of the
renin-angiotensin system. In the two cases described, the etiology
of RTD was linked to mutations in ACE that lead to non-
functional ACE protein in the homozygous state, a frame shift
mutation in the 8
th exon or introduction of a stop codon in the 5
th
exon, both of which resulted in a truncated protein the lacked the
catalytic sites [24].
Herein, we report a mechanism for the 3
rd case of RTD which
was observed in Lisbon, Portugal which is associated with
complete absence of ACE due to a homozygous Q1069R ACE
substitution. We present evidence that this novel mutation
represents a ‘‘transport –defective or -processing’’ mutant
of ACE. Moreover, we demonstrate in a CHO cell expression
model that a combination of chemical (sodium butyrate) or
pharmacological (ACE inhibitor) chaperones with proteasome
inhibitors (MG 132 or bortezomib) significantly restored traffick-
ing of mutant ACE to the cell surface. Therefore, chaperones and
proteasome inhibitors may be clinically useful for restoring cell
surface expression of ‘‘transport –defective or -processing’’
mutant proteins.
Materials and Methods
DNA preparation, linkage analysis and mutation
screening
Peripheral blood was obtained from the affected patient, her
unaffected brother, and her parents by Dr. Rosario Stone
(Hospital de Santa Maria, Lisboa, Portugal) after obtaining
informed consent from parents. Blood samples were sent to
Ho ˆpital Necker-Enfants Malades, INSERM, U574, Universite ´
Paris Descartes, Paris, France. Experiments were done in
accordance with French ethical committee recommendation.
Genomic DNA was isolated by standard methods. Linkage
analyses were performed using microsatellite markers based on
proximity to REN, AGT, AGTR1 and ACE genes as well as marker
heterozygosity (D1S2683, D1S2717, D1S2668, D1S2872 for REN;
D1S479, D1S2833, D1S225, D1S251 for AGT; D3S3618,
D3S1306, D3S1308, D3S3705 for AGTR1; D17S948, D17S944,
D17S1809 and D17S1874 for ACE). Linkage to the ACE locus was
compatible whereas the genes REN, AGT and AGTR1 could be
excluded as the cause of the disease.
We used the Oligo 6.2 program (NBI) to design specific primers
to amplify the coding exons and the adjacent intronic sequences of
the ACE gene (26 exons). The PCR products were treated with
Exo-SAP IT (AP Biotech) and both strands were sequenced using
the dideoxy chain termination method on a 3130XL DNA
sequencer (Applied Biosystems). Sequences were evaluated with
the Sequencer software (Gene Codes, Ann Arbor, MI, USA).
Segregation analysis of mutations in families and 100 unrelated
ethnically matched controls was performed by direct sequencing.
Amino acid conservation at the missense mutations was assessed
using SIFT software (http://sift.jcvi.org/) and Polyphen was used
to predict the effect of the variation on the protein (http://coot.
embl.de/PolyPhen/).
ACE activity assay
Heparinized plasma from patient, her parents and healthy
brother, kindly provided by Dr. Rosario Stone (Hospital de Santa
Maria, Lisboa, Portugal), was taken for determination of ACE
activity. The study was approved by the Institutional Review
Boards of the University of Illinois at Chicago and procedures
followed were in accordance with institutional guidelines. ACE
activity in human plasma was measured using a fluorimetric assay
[26–27]. Briefly, 20–40 ml aliquots of heparinized plasma, diluted
1/5 in PBS + BSA (0.1 mg/ml), were added to 200 ml of ACE
substrate (5 mM Hip-His-Leu or 2 mM Z-Phe-His-Leu) and
incubated at 37
uC. The His-Leu product was quantified by
incubation with O-phthaldialdehyde fluorimetrically at 365 nm
excitation and 500 nm emission wavelengths. Determination of
the ratio of hydrolysis of the two substrates (ZPHL/HHL) was
performed as described [28].
Site-directed mutagenesis and in vitro analysis of mutant
ACE
cDNA encoding mutant ACE protein was provided by Dr.
Tiago Outeiro (Cell and Molecular Neuroscience Unit, Instituto
de Medicina Molecular, Lisboa, Portugal) and was created by
mutation of the CAG codon for Gln at position 1069 to codon
CGG for Arg in pACE-wt, an expression vector based on
pcDNA3.1+/Hygro (Invitrogen Corp., Carlsbad, CA) (provided
by us), containing the full-length somatic ACE cDNA controlled
by CMV early promoter [29]. The exact procedure will be
described and published elsewhere. Plasmids carrying the coding
sequence for wild-type (WT) ACE and mutant ACE (Q1069R)
were expressed in CHO cells using Plus Reagent (Invitrogen
Corp., Carlsbad, CA) for transient transfection and generation of
stable cell lines was performed by selection in G418 containing
media according to manufacturer’s recommendation. CHO cell
lines expressing human recombinant wild-type have been
previously described [29].
Culture medium (Ultra-CHO medium, Cambrex Bio-Science
Walkersville, Inc, Walkersville, MD) from these cells (WT-ACE
and Q1069R) was used as a source of the soluble ACEs, and cell
lysates as a source of membrane-bound ACEs for biochemical and
immunological characterization. To assess the effect of culture
conditions and different compounds on ACE activity and
localization, CHO cells stably expressing WT- and Q1069R-
ACE were cultured in F12 medium containing 10% Fetal Bovine
Serum (FBS). When the cells reached 70–90% confluence they
were washed twice with PBS and fresh Ultra-CHO medium
having no endogenous ACE activity was added. Effect of
temperature (30uC versus 37uC) and inhibitors was assessed:
sodium butyrate (Sigma-Aldrich, St. Louis, MO)-5 mM; ACE
inhibitor enalaprilat (Sigma-Aldrich, St. Louis, MO)-1 mM;
proteosome inhibitors–MG132 (Assay Designs, Ann Arbor, MI)
and Bortezomib (ChemieTek, Indianapolis, IN)-both at 5 mM.
After 24 hrs, the culture medium was aspirated and centrifuged (to
removed detached cells) and the cells, after washing with PBS,
were lysed with 50 mM Tris-HCl buffer, pH 7.5, containing
150 mM NaCl and 0.5% Triton X-100. ACE activity in the lysate
and culture medium was determined using two ACE substrates as
described above.
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Lysates from CHO-WT-ACE cells (with ACE activity of 8 mU/
ml using Hip-His-Leu) were compared to lysates from CHO-ACE–
Q1069R cells normalized by equal protein loading by SDS-PAGE in
4–15% acrylamide Tris-HCl pre-cast SDS PAGE gels (Bio-Red
Laboratories,Hercules,CA).Afterelectrophoretictransferofproteins
to microporous PVDF-Plus membranes, each membrane was
incubated 30 min in 10 mM Tris-HCl (pH 8.0) buffer containing
150 mM NaCl, 0.05% Tween 20, and Western Blocking solution
(Sigma-Aldrich, St. Louis, MO) prior to incubation with hybridoma
culture fluids (1/10 dilution in the same blocking solution) for 1 hr at
room temperature. Subsequent steps were carried with secondary
antibodies (ant-mouse and anti rat IgG, depending on primary
antibody to ACE, conjugated with peroxidase) and peroxidase
activity was developed using SuperSignal WestPico Chemilumines-
cense substrate (Pierce, Rockford, IL).
mRNA quantification
Total RNA was prepared from stably transfected CHO cells
(CHO-WT-ACE and CHO-Q1069R-ACE) using TRIZOL
reagent (Invitrogen Corp., Carlsbad, CA) and treated with DNase
(Ambion., Austin, TX) to remove DNA. RNA was converted to
cDNA by SuperScriptH III Reverse Transcriptase (Invitrogen
Corp., Carlsbad, CA) using random hexamer primers, and mRNA
levels were estimated by quantitative touchdown PCR (QPCR).
PCR was done using Taq DNA Polymerase (Invitrogen Corp.,
Carlsbad, CA) and contained SYBR Green (SybrGreen1 10,0006
concentrate, diluted 1:10,000; Molecular Probes, Eugene, OR).
PCR conditions were 30 cycles of denaturation at 94uC for 10 s;
annealing at 56–62uC for 15 s; and extension at 72uC for 20 s on a
Corbett Rotorgene Real-Time PCR unit (Corbett, Australia).
Relative mRNA concentrations were calculated from the takeoff
point of reactions using manufacturer’s software and normalized
to a-tubulin. Melting curve analysis and agarose gel electropho-
resis ensured production of single and correct-size products. The
primers used were:
a-tubulin forward, CCCTCGCCATGGTAAATACAT;
a-tubulin reverse, ACTGGATGGTACGCTTGGTCT;
ACE forward, TCCGCACGGAGAACGA
ACE reverse, CCTGCTGCGCATCCA
Confocal microscopy
To assess the cell surface and intracellular localization of
exogenously expressed WT- and Q1069R-ACE, CHO cells were
either fixed in 0.3% paraformaldehyde on ice for 15 min, or fixed
and permeabilized with 3% paraformaldehyde at 37uC for
15 min, respectively. Fluorescent secondary Ab (goat anti-mouse
Alexa 488, 1:500) labeling of anti-ACE mAb 9B9 [30] was used to
label and localize WT and Q1069R ACE and nuclei were labeled
with DAPI (1 mg/ml). Traditional line scanning confocal micros-
copy [31] using a Zeiss LSM 510 META microscope, 488 nm
laser excitation/520 nm emission for Alexa 488 fluorescence and
Hg lamp + UV filter set for DAPI, 63x 1.2 NA water immersion
objective, and pinhole set to achieve 1 Airy unit was used to image
the expressed ACE constructs in CHO cells.
Immunological characterization of the mutant ACE (Plate
immunoprecipitation assay)
96-well plates (Corning, Corning, NY) were coated with 50 ml
affinity-purified goat anti-mouse IgG (Pierce, Rockford, IL) at
10 mg/ml and stored overnight at 4uC. After washing with PBS
containing 0.05% Tween 20, the wells were incubated with
different anti-ACE mAbs (2 mg/ml) directed to 16 different
epitopes on the N and C domain of ACE [15–16,30,32–34] in
PBS + 0.1 mg/ml BSA for 2 hrs at RT and washed. Wells were
then incubated with 50 ml of soluble ACE secreted from CHO
cells transfected with wild type or mutant ACE or with lysates from
these cells, resembling a membrane-bound form of ACE (wt and
mutant). These samples (wt versus mutant ACE) were equilibrated
for determination of ACE activity using Z-Phe-His-Leu as a
substrate for 2 hrs at RT. After washing away unbound ACE,
plate-bound ACE activity was measured by adding the ACE
substrate (Hip-His-Leu or Z-Phe-His-Leu) directly into wells [30].
Results and Discussion
Identification of ACE mutation
Diagnosis of Renal Tubular Dysgenesis (RTD) was made in the
first day of life of the patient by Dr. Rosario Stone (Hospital de
Santa Maria,Lisboa, Portugal) based on hypocalvaria,hypotension,
and anuric renal failure. Clinical characterization of this case will be
published elsewhere. Based on the results of Gribouval et al. [24], it
was proposed that the homozygous lost-of-function mutation in one
of the genes responsible for AII-dependent signaling – angiotensin-
ogen (AGT), renin (REN), angiotensin-converting enzyme (ACE),
or the receptor for angiotensin II (AGTRI), might be responsible for
the phenotype. Genomic DNA from this patient, her parents and
healthy brother was sent to Dr. M-C. Gubler (Ho ˆpital Necker-
Enfants Malades, INSERM, U574, Universite ´ Paris Descartes,
Paris, France).
Sequencing of the 26 exons of the ACE gene led to the
identification in exon 22 of the c.3293A.G (p.Q1098R) mutation
in the homozygous state in the patient and the heterozygous state
in each parent and the patient brother. In mature somatic ACE
protein (without signal peptide-mature somatic ACE numbering
[13] it correspond to Q1089R. This mutation was found in both
parents and in the brother of the patient in the heterozygous state.
According to database search (http://www.ncbi.nlm.nih.gov/
projects/SNP/), there is no variant in ACE exon 22 and screening
results revealed that none of the 100 healthy controls showed this
mutation indicating that this substitution is not a polymorphism.
This mutation results in substitution of a highly conserved
glutamine with lysine in position 1069 in the C-terminal domain
of ACE. The amino acid change is not tolerated according to
SIFT software and Polyphen predicts this mutation is probably
damaging with a score at 1.868.
ACE activity determination in the affected family
Plasma ACE activity of the patient and immediate family were
measured and showed that the patient had no ACE activity
whereas both parents and a brother had approximately two-times
less ACE compared to healthy individuals (Figure 1). Figure 1A
shows ACE activity (cleavage of substrate Hip-His-Leu) in
heparinized plasma of 5 healthy individuals and the 4 members
of the affected family. Figure 1B, which shows the ratio of the rate
of hydrolysis of two ACE substrates, Z-Phe-His-Leu and Hip-Hi-
Leu (ZPHL/HHL ratio, used to characterize the N and C
domains of ACE and thereby assess the nativity of somatic ACE
[28], was not different in the parents and brother compared to
ACE activity ratio of normal volunteers. If the reduction in ACE
activity of the family was due to mutation in the C domain active
center of somatic ACE, the ratio would have been expected to
increase [28]. A ZPHL/HHL ratio for the index patient was not
determined since no measurable ACE activity was discernable
using either substrate. Furthermore, as revealed in Figure 2, the
novel ACE mutation identified (Q1069R substitution) is unlikely to
affect the catalytic properties of the C-domain active center and
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Analysis of the 3D-structure of the C domain demonstrated that
Gln1069 is close to the surface of the C domain and thus far way
from the active site making it unlikely that it would have a direct
effect on the catalytic activity (Fig. 2).
Characterization of Q1069R ACE Mutant
There are several possibilities as to why this particular mutation
leads to absence of ACE protein in the plasma and presumably the
surface of endothelial cells (the main source of circulating ACE).
We hypothesized that the absence of plasma ACE could be due to
destabilization of mRNA, proteolytic cleavage by intracellular
proteases as a result of misfolding of the mutant protein, and
impaired trafficking of the mutant to the plasma membrane.
Previously, we showed that dendritic cells (DC) originating from
Acute Myeloid Leukemia (AML) blasts has no cell surface ACE, in
sharp contrast to DC generated from monocytes of healthy donors
[10]. Furthermore, we demonstrated that this was due to impaired
trafficking of ACE from the cytosol to cell surface in AML blasts
and we were able to restore normal trafficking by treatment with
chemical chaperones (sodium butyrate) or cultivation at low
temperature (30uC)[Galtseva et al. in preparation].
Several ACE glycosylation mutants that do not have ACE
catalytic activity, when transfected into CHO cells (for example a
mutation in the N domain in which 4 glycosylation sites are
removed, provided by Dr. E. Sturrock, University of Cape Town,
South Africa) showed significant ACE catalytic activity after
cultivation at lower temperature or in the presence of sodium
butyrate-data not shown- personal communications). Therefore,
we hypothesized that the new mutation in ACE (Q1069R
substitution) caused misfolding of ACE and impaired trafficking
of ACE from the endoplasmic reticulum to the cell surface, and
thus accumulated inside the cells.
Site-directed mutagenesis of human recombinant
somatic ACE
To decipher the mechanism by which the novel Q1069R
mutation might be responsible for the absence of plasma (and
perhaps tissue) ACE in the affected individuals, we performed site-
directed mutagenesis of human recombinant somatic ACE,
generated this mutant of somatic ACE in CHO cells, and
compared the biochemical and immunological characteristics of
this mutant with WT somatic ACE.
Western Blotting. For the initial characterization of mutant
ACE produced by CHO cells, we performed Western blotting of
cell lysates from CHO-WT-ACE and CHO-Q1069R-ACE using
several mAbs to denatured human ACE: mouse mAb 1D8, 3C5,
and 2E2, which recognize sequential epitopes in the C domain
[35–37], as well as rat mAb 4G6, that recognizes an epitope on the
mouse and human N domain [38]. Fig. 3A showing the Western
blot of human ACE using mAb 4G6 demonstrates the classical
duplet bands, reflecting the fully glycosylated form of recombinant
WT ACE (higher MW band) and the unglycosylated form of
recombinant ACE (minor band)[39]. The width and density of the
mutant ACE band was much smaller, reflecting a reduced amount
of mutant ACE produced by CHO cells from an equivalent
number of cells. Similar results were obtained by Western blotting
these samples with 3 other mAbs to ACE (not shown). Because the
cell lysates were normalized to total cell protein, the dramatic (5-
fold) difference in amount of WT and mutant ACE protein
(Fig. 3B) might be explained by a reduction in the level of mRNA
for mutant ACE (for example due to the effect of this mutation on
mRNA stability) or due to intracellular proteolysis of misfolding of
mutant ACE.
mRNA quantification. In order to determine the reason for
the dramatic decrease of mutant ACE protein in transfected CHO
cells, we quantified mRNA production by CHO-ACE-WT and
the mutant Q1069R. Fig. 3C convincingly demonstrates that
c.3293A.G substitution did not decreases the synthesis of mRNA
of mutant ACE; rather, the mutant showed even greater ACE
mRNA was being produced. Therefore, we should concluded that
the dramatic decrease in total mutant ACE protein produced by
CHO cells transfected with plasmid coding for mutant (Q1069R)
ACE was due to intracellular proteolysis of misfolded mutant
ACE.
Immunostaining and Confocal Microscopy. Confocal
microscopy was used to determine the subcellular localization of
WT- vs. Q1069R-ACE mutant expressed in CHO cells following
immunostaining with anti-ACE mAb 9B9. Fig. 4A shows
abundant membrane localization of WT-ACE in lightly fixed-
non-permeabilized cells, whereas we did not observe membrane
localization of mutant Q1069R-ACE under the same conditions
and detector settings (Fig. 4D). To determine whether mutant
ACE was expressed, but localized intracellulary, CHO cells were
Figure 1. Plasma ACE activity of the members of the affected
family. ACE activity in heparinized plasma (1/5 dilution in PBS) of
members of the affected family, the father (F), mother (M), and brother
(B) as well as in 5 healthy individuals (marked by initials) that served as
controls was determined by fluorimetric assay of 40 ml diluted plasma
with 200 ml each of substrates Hip-His-Leu (HHL) and Z-Phe-His-
Leu(ZPHL) during 1 hour of incubation. A. ACE activity with HHL:
mean (6 SD) of three independent determinations. B. Ratio of
hydrolysis of the two substrates (ZPHL/HHL ratio) in the tested
samples, which is used to characterize for each catalytic domain of ACE
in somatic two-domain ACE [28]. ND-not determined. * p,0.05 vs.
control samples.
doi:10.1371/journal.pone.0010438.g001
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37uC (Fig. 4C and 4F). In WT-ACE expressing cells, ACE was
observed primarily on the plasma membrane and to a lesser extent
in the cytosol (Fig. 4C), whereas Q1069R-ACE was found mainly
in perinuclear areas (Fig. 4F). The perinuclear distribution of
mutant ACE is consistent with retention of the protein in the ER
and/or Golgi (Fig. 4F). Thus, compared to the non-permeabilized
cells, WT-ACE immunostaining remained primarily associated
with the plasma membrane whereas Q1069R-ACE immuno-
localization was observed typically on one side of the nucleus
(Fig. 4F). To clarify whether the trafficking defect of mutant ACE
could be rescued and thus restore ACE localization to the plasma
membrane, cells were treated with the chemical chaperone sodium
butyate and proteasome inhibitor MG132. In WT-ACE
expressing cells, treatment with the combination of sodium
butyrate acid and MG132 resulted in enhanced ACE
immunostaining on the plasma membrane (Fig. 4B). Q1069R-
ACE immunostaining was more abundant than in permeabilized
cells and it was localized on the membrane following sodium
butyrate and MG132 treatment suggesting the pharmacologic
agents stimulated trafficking to the surface and also prevented
ACE degradation (Fig. 4E). A cytotoxic effect of the drug
treatments was also observed (cell rounding and nuclear
fragmentation). Therefore, these studies indicate that the
Q1069R-ACE mutation impairs trafficking to the cell surface
and promotes degradation by intracellular proteases.
During the last 20 years, numerous ACE mutations have been
generated (more than 40) and among them, several where
identified which had no enzymatic activity but measurable mRNA
expression or ACE protein production; these were shown to be
due to mutations of potential glycosylation sites. Thus several
multiple and single glycosylation mutants were characterized by
the arrest of mutant protein in the endoplasmic reticulum and by
rapid intracellular degradation [40–41] (Sturrock ED, personal
communication). Two ACE chimeras were generated by substi-
tuting regions of the C domain with corresponding N domain
sequences which also demonstrated defective intracellular pro-
cessing, were enzymatically inactive, and did not localize to the cell
surface [42]. A deletion of 4 amino acid residues -D9NFSA12 [43],
and a single S528C substitution, [Danilov, unpublished observa-
tion] that destroys one of the disulfide bridges in the N domain
[44] also prevented proper intracellular processing of mutant ACE
and lead to fast intracellular degradation. Furthermore, a new
human ACE mutation (D1141–1152 in the C domain of ACE)
found recently in Japan [45] also likely led to the arrest of
intracellular processing and rapid degradation. Therefore, it seems
that impaired trafficking and fast intracellular degradation as a
result of Q1069R ACE mutation is not unique for ACE.
ACE activity of the mutant ACE. Kinetic analysis of soluble
mutant ACE as well as membrane bound mutant in comparison
with WT ACE using two widely used ACE substrates showed a
very unexpected result. ACE activity of the lysates of CHO cells
expressing mutant human ACE determined with Hip-His-Leu was
very low and consisted of about 2.6% of the WT ACE activity in
CHO cells (Fig. 5A). This value is significantly lower than the
amount of mutant ACE revealed by Western blotting (10–20%;
Fig. 3B). However, it was expected, because we and others
demonstrated previously that catalytically active ACE localized on
the cell surface represents only part of the total ACE produced by
cells [6,46–47]. The remaining ACE protein in cells represents
immature ACE, perhaps still containing the signal peptide [40], is
catalytically inactive [6,47], perhaps due to improper folding.
Western blotting, which was performed with mAbs recognizing
denatured epitopes (Fig. 3A), reflects both mature and immature
ACE in the cells, with the immature, inactive ACE localized inside
cells and mature, catalytically active ACE localized to the cell
surface. ACE activity of lysates is thus only a measure of mature,
catalytically active ACE on the cell membrane.
ACE activity in cell lysates of CHO-Q1069R-ACE cells
determined using the substrate Z-Phe-His-Leu was significantly
greater (14.1%) than observed with Hip-His-Leu (2.6%), although
still much less than WT ACE (Fig. 5A). Therefore, the ZPHL/
Figure 2. Localization of new mutation (Q1069R) in the C domain of somatic ACE. The localization of Gln1069 in the C-domain of human
ACE which was mutated to Arg is shown using molecular surface (A) and ribbon (B) representations of the substrate-bound crystal structure of the C-
domain fragment of human ACE, where the 36 amino acid residues unique to tACE were deleted [75]. The surface and ribbon are light brown, and
amino acid residues that were crucial for orientation are colored. Key amino acids referred to in the text are denoted using somatic ACE numbering.
Gln1069 (brown) is located right under the bump created by Lys1067 and Tyr1068 (purple) and shown by arrow. Dark blue indicates the first N-
terminal amino acid residue (Asp616) seen in this structure; orange-indicates the C terminal end of the C-domain (and the epitope for mAb 1B3;
[16,36]. Light blue (P730) and red colored amino acid residues indicate highly immunogenic bumps on the surface of the C-domain. Light green
indicates Asp in putative glycosylation sites.
doi:10.1371/journal.pone.0010438.g002
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ACE (Fig. 5B). The same difference in this ratio was observed for
soluble ACE in the culture fluid (not shown).
The two domains of ACE hydrolyze the same range of natural
and synthetic substrates, but with rather different efficiencies
[48–51]. The two synthetic substrates - Z-Phe-His-Leu (ZPHL)
and Hip-His-Leu (HHL) are used for determination of ACE
activity in laboratories worldwide, mostly at fixed concentrations,
2 mM and 5 mM, respectively. These two substrates display some
contrasting enzymatic properties: the C domain of human ACE
hydrolyzes HHL at a much faster rate (9-fold) compared to the N
domain [48], whereas ZPHL is hydrolyzed at an almost equal rate
by both domains [30]. As a result, the ratio of the rates of
hydrolysis of these two substrates (ZPHL/HHL ratio) is charac-
Figure 3. Mutant ACE protein and mRNA quantification. CHO cells were transiently transfected with plasmids coding for wild-type (WT) and
mutant (Q1069R) ACE (4 mg of plasmid DNA per 35 mm dish). The lysates of these cells (normalized by equal protein loading of 10 mg per lane) were
subjected to SDS-PAGE (4–15% gradient gel) in reducing conditions for Western blotting (A) or ACE mRNA quantification (C). A. Western blotting was
performed with rat mAb (4G6) that recognizes the denatured epitope on the N-domain of human ACE [38]. Proteins transferred on PVDF-Plus
membrane were revealed with 2 mg/ml of indicated mAb. Molecular weight markers are shown by arrows on the left of panel A, which is a
representative experiment. B. The relative amount of WT and mutant ACE revealed by Western blotting with mAb 4G6 (A) was quantified by the
image analysis (densitometry) using ImageJ software (NIH). Data are expressed as mean 6 SD of 3 independent experiments. C. Relative mRNA
concentrations were calculated from the takeoff point of reactions using manufacturer’s software and normalized to a-tubulin. Data are expressed as
mean 6 SD of 3 independent experiments.
doi:10.1371/journal.pone.0010438.g003
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about 1–1.5, N-domain – 5–7, and C-domain - 0.6–0.8 [28,52].
We also demonstrated that selective inactivation or inhibition of
the C-domain in somatic ACE increases this ratio from 1 toward
higher values more characteristic for the N-domain, whereas
selective inactivation or inhibition of the N-domain in somatic
ACE decreases the ratio toward lower values predicted for C-
domain substrate hydrolysis [28].
Data from Fig. 5C indicate that mutant ACE has no functional
C-domain active center or that this mutation abolished substrate
specificity of the C-domain. The C-terminal domain of WT
human ACE cleaves Hip-His-Leu much faster than the N-domain,
whereas the N-domain cleaves substrates such as LH-RH and
AcSDKP much more efficiently [48–51].
We (and others) hypothesized that several amino acid residues
might determine a significant substrate specificity of the N- and C-
domains. Based on analysis of the rate of hydrolysis of different
substrates and the response to different inhibitors and effectors
(sulfate ions, dinitrofluorobenzene) by ACE from different species,
we hypothesized that the amino acid residues Ser858, Met907,
Lys1005, Glu1029, Val1104 in the C-domain might determine
preferential hydrolysis of HHL by the C-domain and low
efficiency of HHL hydrolysis by the N-domain, giving rise to a
high ZPHL/HHL ratio for the truncated N-domain [Danilov,
unpublished observation]. Recently, analysis of the 3D structure of
the C-domain with novel C-domain selective inhibitors revealed
several amino acid residues that may contribute to the domain
specificity of ACE inhibition [53]. Interestingly, two residues -
Ser858 and Glu1029 (out of 10 suspicious residues), were as we
predicted. Furthermore, the structural basis for substrate specific-
ity of the N- and C-domain active centers was partially resolved by
systematic mutagenesis of the suspected residues in truncated N-
and C-domains. The amino acid residues in the C-domain and N-
domain determine (at least in part) the substrate specificity and
reason for the low ZPHL/HHL hydrolysis ratio for the C-domain
and high ratio for the N-domain (Sturrock ED, personal
communications).
A closer look to the structure of the active center of the C-
domain ruled out the possibility that the Q1069R substitution is
responsible for the dramatic increase in ZPHL/HHL ratio of
mutant ACE. Figure 6 clearly shows that the distance between
Q1069 (or R1069 after substitution) and the proline of the ACE
inhibitor lisinopril is about 8 A ˚, which is too far for a direct
interaction with substrates or interference with the residues in the
C-domain active center responsible for substrate specificity or
domain specificity of ACE inhibition [53]. Therefore, the more
likely reason for the apparent non-functional C-domain of mutant
Q1069R ACE may be selective denaturation of the C-domain.
Immunological characterization of the mutant ACE. We
developed a set of mAbs that recognized 16 different
Figure 4. Differential subcellular localization of wild type and mutant ACE. Confocal microscopy was used to determine the localization of
WT- vs. Q1069R-ACE mutant expressed in CHO cells following immunostaining with anti-ACE mAb 9B9 and Alexa 488 goat anti-mouse secondary Ab.
A-C: WT-ACE expressing cells; D-F: Q1069R-ACE expressing cells. A,B and D,E. Immunostaining of WT and Q1069R ACE in 0.3% paraformaldehye for
15 min at 4C (fixed only). B and E. Treatment with the chemical chaperone sodium butyrate and proteosome inhibitor MG132 for 24 hrs followed by
immunostaining with 9B9 mAb. C and F. CHO cells fixed and permeabilized with 3% paraformaldehyde for 15 min at 37C and labeled as above show
WT-ACE on the plasma membrane and to a lesser extent in the cytosol and Q1069R-ACE in perinuclear areas.
doi:10.1371/journal.pone.0010438.g004
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of human ACE useful for epitope mapping. Eight mAbs recognize
epitopes on the catalytically active N-domain [15,30,32–34] and 8
mAbs recognize epitopes localized on the C-domain of ACE
[16,36]. We recently demonstrated that the pattern of
precipitation of ACE activity (conformational fingerprinting of
ACE) using this set of mAbs provides a sensitive means of
identifying changes in local conformation of ACE due to
inactivation, inhibition, mutations, etc. [Danilov et al, 2010, in
preparation). Moreover, we successfully used this set of mAbs to
detect several new human ACE mutations and characterized the
conformation of Pro1199Leu [54] and Trp1197Stop ACE
mutations [55].
We thus immunoprecipitated mutant membrane-bound ACE
from lysates of CHO cells expressing WT vs. Q1069R ACE (as
well as soluble ACE from culture fluids from these cells) to
fingerprint the conformation of the mutant. The ability of each
mAb to immunoprecipitate ACE is influenced by the local ACE
conformation which of course can be influenced by changes of
amino acid sequence induced by genetic mutations or by local,
selective denaturation. As clearly apparent from Fig. 7, the
immunoprecipitation profile of mutant ACE differs dramatically
from that of WT ACE. The overall precipitation of ACE activity
by mAbs directed to the epitopes localized on the N-domain did
not changed dramatically; the Q1069R/WT ratio of ACE activity
precipitation for 7 mAbs to N domain calculated from the data
presented in Fig. 7 was 1.0160.38. The ratio for mAb 3A5 was
not included in the calculation because this mAb is strongly anti-
catalytic and changed significantly the catalytic characteristics of
the N-domain of somatic WT ACE [28,33]. However, the local
conformation of certain regions of the N-domain of mutant
Figure 5. ACE activity of mutant ACE. ACE activity of the membrane-bound form of ACE in lysates of CHO cells expressing WT and mutant ACE
was determined by fluorimetric assay of 40 ml aliquotes of cells with 200 ml each of substrates Hip-His-Leu (HHL) and Z-Phe-His-Leu (ZPHL) during
1 hr incubation. A. ACE activity with HHL and ZPHL (mU/ml), correspondingly, from a representative experiment performed in triplicate. B. Ratio of
hydrolysis of the two substrates (ZPHL/HHL ratio) in the tested samples. The data are presented as mean (6 SD) from three independent
experiments. *p,0.05 vs. control samples.
doi:10.1371/journal.pone.0010438.g005
Figure 6. Localization of critical residues in the active center of
the C-domain. The localization of amino acid residue Arg1069 relative
to the active center of the human ACE C-domain is shown in the ribbon
representation of the substrate-bound crystal structure of the C domain
fragment in which the 36 amino acid residues unique to tACE have
been deleted [75]. Key amino acids referred to in the text crucial for
substrate specificity and ACE inhibition are denoted by somatic ACE
numbering. Arg1069 is located more than 8 A ˚ from the nearest residue
(Pro) of ACE inhibitor enalaprilat shown in yellow.
doi:10.1371/journal.pone.0010438.g006
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of overlapping epitopes for mAbs 9B9, 3G8, and i1A8 [30,32,43]
visibly increased, whereas binding of mAbs 1G12 and 6A12 whose
epitopes also overlap [15,30] decreased. Precipitation of ACE
activity by all mAbs raised against the C-domain was dramatically
reduced. Overall, the Q1069R/WT ratio for the 8 mAbs to the C-
domain dropped more than 5-fold (0.1860.04, p,0.05 in
comparison with this parameter for mAbs to the N-domain).
The same pattern was characteristic for soluble WT and mutant
ACE (data not shown). This data unequivocally indicates that a
dramatic increase in kinetic parameters of mutant ACE (ZPHL/
HHL ratio) was due to selective denaturation of the C-domain of
mutant ACE, perhaps due to incorrect chaperoning and more
defective trafficking to the cell surface. Moreover, selective
denaturation of the C-domain also changed the conformation of
regions in the N-domain of ACE.
Increased fragility of the C-domain in comparison with the N-
domain was demonstrated first by studying thermal stability of the
separated N- and C-domains [56–58]. The C-domain was
thermally less stable than the N-domain even in native somatic
ACE, as demonstrated first by differential scanning colorimetry
[57] and later using a kinetic approach utilizing the ratio of the
rate of hydrolysis of two substrates for ACE -ZPHL/HHL ratio
[28]. The C-domain was also more susceptible to proteolytic
degradation than the N-domain [59–60]. Therefore, these data
provide the basis for suggesting that selective denaturation of the
C-domain in mutant ACE which leads to kinetic inactivation of
the C-domain active center might be due to the more labile nature
of the C-domain as it appears to be less resistant to the effect of
chaperones that traffic the misfolded mutant to the cell surface and
less resistant to intracellular proteolysis.
Selective inactivation of the active center in the C-domain and
partial denaturation of this domain was confirmed by analysis of
mutant Q1069R ACE inhibition by ACE inhibitor enalaprilat and
by anti-N-domain catalytic mAbs 3A5 and i2H5 (Fig. 8).
Inhibition of WT ACE mediated Hip-His-Leu hydrolysis was
much more profound than inhibition of ZPHL hydrolysis (Fig. 8A).
This might be explained by the preferential inhibition of the C-
domain active center in native ACE by commercial ACE
inhibitors [28,61] and by preferential hydrolysis of HHL by the
C-domain active center [48], whereas the anti-catalytic activity of
enalaprilat on mutant ACE (which contains only the N-domain
active center) was similar with both substrates (which corroborates
well with the fact that the rate of hydrolysis of these two substrates
by the N-domain active center is similar [30]. Inhibition of ACE
activity (HHL cleavage) in WT ACE by anti-catalytic mAbs
towards N domain was practically absent due to this reason,
whereas their action on ZPHL hydrolysis was visible, but did not
reach 50% inhibition at the concentration of mAbs used because
these mAbs inhibited only the N domain center and hydrolysis of
Figure 7. Conformational fingerprinting of mutant ACE. Membrane-bound WT and mutant ACE lysates were normalized to achieve 5 mU/ml
ACE activity with Z-Phe-His-Leu as substrate and incubated in microtiter plate wells covered with 16 mAbs to human ACE [16,30] via goat-anti-mouse
IgG. Precipitated ACE activity was quantified by fluorimetric plate precipitation assay [30,54]. Data (mean 6 SD of 6–8 independent experiments in
duplicate) are expressed as ratio of ACE activity precipitated by mAbs from mutant ACE to that of WT ACE. * p,0.05 vs. WT ACE.
doi:10.1371/journal.pone.0010438.g007
Transport-Defective ACE Mutant
PLoS ONE | www.plosone.org 9 May 2010 | Volume 5 | Issue 5 | e10438the substrates in the C-domain was not disturbed. The anti-
catalytic affect of these mAbs was quit profound towards mutant
ACE, confirming that the hydrolysis of the substrates by mutant
ACE was performed mainly by the N-domain active center.
We also assessed ZPHL/HHL hydrolysis by mutant ACE
bound to antibodies. Fig. 9 demonstrates that the ZPHL/HHL
ratio of WT ACE did not significantly change relative to WT ACE
in solution (horizontal line in Fig. 9A). However, selective
denaturation of the C domain of mutant ACE (as demonstrated
in Fig. 7) was partially restored after binding to some of the mAbs.
The ZPHL/HHL ratio for the mutant ACE precipitated by mAbs
to the N-domain was the same as for mutant ACE in solution
(horizontal line at Fig. 9B), whereas the ZPHL/HHL ratio for
mutant ACE trapped by some mAbs to the C-domain significantly
decreased, demonstrating a movement toward lower values
characteristic of native two-domain ACE (Fig. 7B). mAb is 1B3
directed to an epitope close to the C-terminal end of the C-
domain, whereas mAbs 2H9, 3F11 and 2B11 recognize highly
overlapping epitopes on the other side of C-domain globule [16].
We confirmed that this chaperone-like effect of these mAbs to
ACE was also retained when mutant ACE was in solution as in the
situation described in Fig. 8. Fig. 10 demonstrates a dose-
dependent decrease of ZPHL/HHL ratio for mutant ACE
indicative of partial renaturation after adding mAb 1B3. mAb
Figure 8. Effect of ACE inhibitors and anti-catalytic mAbs on mutant ACE activity. Lysates form CHO cells expressing mutant and WT
membrane-bound ACE were incubated with ACE inhibitor enalaprilat (10
29–10
28 M) (A) and with mAbs (10 mg/ml) (B) which are anti-catalytic for the
N-domain active center (i2H5 and 3A5- [30,33]. Residual ACE activity was determined as in Fig. 5.
doi:10.1371/journal.pone.0010438.g008
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negative control. It is interesting to note that the chaperone-like
effect of mAb 1B3 was similar for membrane-bound mutant ACE
(Fig. 10A) and for soluble mutant ACE (Fig. 10B). This effect of
mAb 1B8 was very modest for membrane-bound ACE (Fig. 10A)
and more profound in the case of soluble ACE (Fig. 10B), which is
consistent with the fact that the epitope for mAb 1B8 is more
exposed on soluble ACE in comparison with membrane-bound
ACE [16].
A chaperone-like effect of the mAbs and the partial or complete
renaturation of reversibly denatured protein conformations were
previously demonstrated for other antigens [62–64]. Chaperone-
like antibody activity may be due to stabilization of native antigen
conformations, folding transition states, or screening of aggregat-
ing hydrophobic surfaces [63].
Pharmacological rescue of conformation-defective ACE
mutant
There are now hundreds if not a thousands of examples of
transport-defective mutations to proteins. Mutations resulting in the
changes in protein sequences often result in the production of
misfolded and disease-causing proteins that are transcribed and
translated at normal levels but are unable to reach their functional
destination in cells (for review see Sanders and Nagy, [65]. Misfolding
resultsinloss-of-function ofthe conformationallydefective proteinvia
degradation through the polyubiquitination/proteasome pathway
[66]. One of the best described examples of a transport-defective
mutation is the deletion of Phe508 in the cystic fibrosis transmem-
brane conductance regulator (D F508 CFTR). The defective protein
retains substantial chloride-channel function in cell-free lipid
membranes, but when synthesized, the protein is rapidly recognized
as misfolded and is degraded shortly after synthesis beforeit can reach
its crucial site of action at the cell surface [67]. Alternatively,
misfolded proteins may aggregate, leading to potentially toxic
intracellular accumulation of even to protein accumulation in plasma
with extracellular amyloid deposits. Well described examples of such
scenario’s are observed in neurodegenerative disorders such as
Alzheimer’s Disease, Parkinson’s Disease, Huntington Syndrome,
and prion and motor neuron disorders [68].
In the past decade, extraordinary efforts have been made to
understand how abnormal folding relates to certain pathologies
and to design therapeutic interventions that prevent or correct the
structural abnormality of the disease-causing misfolded proteins.
In this regard, rescue of misfolded ‘‘trafficking-defective’’ proteins
by chemical and pharmacological chaperones and by inhibitors of
intracellular degradation is emerging as one of the most promising
therapeutic strategies for such disorders [69–71].
The clarification of the molecular mechanism of this particular
ACE mutation has not only scientific, but also clinical value. If the
treatment of CHO cells expressing mutant ACE with a
combination of chemical and pharmacological chaperones for
ACE and proteasome inhibitors can effectively restore ACE
Figure 9. Catalytic properties of mutant ACE bound to ACE mAbs. Membrane-bound WT (A) and mutant ACE (B) lysates were normalized to
achieve 5 mU/ml ACE activity with Z-Phe-His-Leu as substrate and incubated in microtiter plates covered by 16 mAbs to human ACE as in Fig. 7. ACE
activity precipitated by each mAb was quantified by fluorimetric assay with two substrates (Hip-His-Leu and Z-Phe-His-Leu) as in Fig. 5. Data are
expressed as the ratio of ACE activity precipitated by each mAb determined with each substrate. Data are mean 6 SD of 6–8 independent
experiments in duplicate. * - p,0.05 vs. ZPHL/HHL ratio for corresponding values of WT and mutant ACE in solution (horizontal lines in A and B). The
ratio for duplicate samples of WT ACE or mutant ACE was approximately 1.0 and the SD was less than 10%.
doi:10.1371/journal.pone.0010438.g009
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that these treatments may also increase ACE trafficking and
thereby prevent fast intracellular proteolysis in patients. We
hypothesize herein that ACE inhibitors might also be considered
as pharmacological chaperones for ACE.
In order to improve the trafficking of mutant ACE to the cell
surface, we cultivated CHO cells expressing mutant and WT ACE in
various conditions known to increase trafficking of proteins to the cell
surface and prevent intracellular degradation. Fig. 11 demonstrates
that culturing at low (30uC) temperature or with addition of chemical
chaperone (sodium butyrate), pharmacological chaperone (ACE
inhibitor), or proteasome inhibitor (MG132 or bortezomib) alone or
in combination dramatically increased cell surface expression of
mutant ACE.ACE activity in lysates of CHO cellsexpressing mutant
ACE significantly increased as a result of such an intervention and
reached approximately 60% of that of WT ACE. A significant effect
of these compounds or low temperature was also observed on the
trafficking of WTACE, though the magnitude of the changes was less
than that observed with mutant ACE. A similar response to treatment
with chemical chaperones rescued the trafficking of mutant bone
morphogenetic protein receptor II (BMPR-II), and thus impaired
trafficking was demonstrated to be responsible for the development of
pulmonary hypertension [72].
We should note that a combination of similar treatments, for
example low temperature and sodium butyrate, did not show an
additive effect (data not shown), whereas the combination of low
temperature with the proteasome inhibitor bortezomib had a
profound additive effect (Fig. 11). Therefore, we believe that
Figure 10. Chaperone-like effect of anti-ACE mAbs on mutant ACE. Membrane-bound (A) and soluble (B) mutant ACE (Q1069R) were pre-
incubated with N-domain specific mAb 9B9 [30] or C-domain specific mAbs 1B3 and 1B8 [16,36] at the indicated concentrations for 2 hrs at room
temperature and then residual activity was determined with 5 mM HHL and 2 mM ZPHL as substrates. Experimental conditions are as described in the
legend to Fig. 5. Data presented as ZPHL/HHL ratio of ACE activity in the presence mAb. Results shown are the mean 6 SD of 3–4 experiments.
doi:10.1371/journal.pone.0010438.g010
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may restore (at least partially) impaired trafficking of mutant ACE
to the cell surface in patients.
Based on these results (Fig. 11) and the fact that the parents of this
patient have approximately two-times less ACE compared to the
population norm (Fig. 1), such an approach might work for patients
with this mutation (Q1069R) and perhaps others, such as the patient
in Japan with the D1141–1152 ACE deletion in the C-domain [45].
The complete absence of ACE during fetal development caused
structural malformations of the renal tubular system of the index
patient. Thus, it is possible that restoration of impaired ACE
trafficking to the surface of ACE expressing cells after treatment
with chemical or pharmacological chaperones and the generation
of AII by renal proximal tubule epithelial cells may not improve
clinical symptoms in this patient. However, there are at least two
arguments based on mouse models that did not develop anuria but
had urine concentrating defects that support the hypothesis and
goal of improving clinical symptoms in this patient.
First, the ACE.2 strain of mice developed by the K. Bernstein
lab [73] show an unusual pattern of RNA splicing resulting in
animals with approximately 1/3 normal plasma ACE activity.
However, these mice completely lacked tissue ACE activity. The
major difference between the ACE.2 mice and ACE null mice
completely lacking ACE activity was the renal pathology. The
ACE.2 mice presented with a much milder form of the renal
medullary and papillary underdevelopment. In the majority of
these animals, renal medullary development was approximately
equivalent to that of WT mice. However, despite relatively normal
renal architecture, the ACE.2 mice were unable to effectively
concentrate urine [73]. When this team correlated the ability to
concentrate urine with renal pathology among individual animals,
they observed examples of mice with perfectly normal renal
medullas that were functionally equivalent to the ACE null mice in
their inability to concentrate urine. These results imply that the
ability to generate angiotensin II locally within the kidney plays a
critical role in the ability to properly concentrate urine.
The second argument comes from studies demonstrating that
administration of exogenous angiotensin II caused a restoration of
tubuloglomerular feedback (TGF) responsiveness to 71% of control in
heterozygous and to 62% of controli nh o m o z y g o u sA C En u l lm i c e .
These data support previous conclusions that angiotensin II is an
essential component in the signal transmission pathway that links the
macula densa with the glomerular vascular pole [74].
Thus, we identified the molecular mechanism by which a novel
mutation of ACE in which codon CAG coding for Gln at position
1069 is substituted in both alleles by codon CGG for Arg results in
nearly complete arrest of intracellular processing and trafficking of
ACE to the cell surface. Due to this arrested, the misfolded mutant
ACE becomes muchmore susceptibleto proteolysis, undergoes rapid
intracellular degradation, and does not traffic to the surface of ACE
expressing cells like endothelial cells of capillaries or epithelial cells of
the kidney. As a result, development of the proximal tubules was
impaired and the patient developed renal tubular dysgenesis.
We characterized the molecular basis of defective ACE
processing due to this mutation using a cellular CHO expression
model in which mutant ACE (Q1069R) activity, immunoreactiv-
ity, and trafficking could be defined. Using a novel conformational
fingerprinting approach for ACE, we demonstrated that mutant
ACE was selectively denatured. The C-domain of somatic ACE
was practically non-functional and only the N-domain active
center was able to cleave ACE substrates. Moreover, using this
model we were able to prevent, to some extent, intracellular
degradation of misfolded mutant ACE, and, to rescue, to some
degree, trafficking of mutant ACE to the cell surface.
Therefore, this study provides important insights into the
mechanism by which the novel ACE mutation (Q1069R) results in
dysfunctional membrane ACE expression due to a trafficking
defect as well as severe renal tubular dysgenesis. Moreover, we
demonstrated an in vitro approach to partially rescue impaired
trafficking of mutant ACE to the cell surface. It may be that such
an approach might result in attenuation of clinical symptoms of
patients with this or similar mutations.
Figure 11. Effect of temperature, chaperones, and proteolytic inhibitors on ACE activity. ACE activity of membrane-bound form of WT
and mutant ACE after culturing cells 24 hrs in different conditions listed below as described in Materials and Methods. ACE activity was determined
by fluorimetric assay as described in the legend to Figure5 using Z-Phe-His-Leu (ZPHL) as substrate. The following compounds were tested: Sodium
butyrate (5 mM); Enalaprilat (1 mM), MG132 (5 mM), Bortezomib (5 mM). Data are the mean values (6 SD) of 3–4 independent experiments measured
in duplicate expressed as the percentage of ACE activity in the lysate of WT or mutant ACE expressing cells cultured at 37uC.
doi:10.1371/journal.pone.0010438.g011
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